Skip to main content
Journal cover image

Phase 1 Clinical Results for NP10679, a pH-sensitive GluN2B-selective N-methyl-d-aspartate Receptor Inhibitor.

Publication ,  Journal Article
Zaczek, R; Traynelis, SF; Dingledine, R; Koszalka, GW; Laskowitz, DT
Published in: Clin Pharmacol Drug Dev
July 2023

NP10679 is a context-dependent and subunit-selective negative allosteric modulator of N-methyl-d-aspartate (NMDA) receptors. It is a more potent inhibitor of GluN2B-containing NMDA receptors at the acidic levels of extracellular pH (eg, 6.9) found in the penumbral regions associated with cerebral ischemia than at physiological pH. This property allows NP10679 to act selectively in ischemic tissue while minimizing the nonselective blockade of NMDA receptors in healthy brain, thereby reducing on-target adverse effects. We report the results of a first-in-human pharmacokinetic and safety phase 1 clinical trial in healthy volunteers receiving single or multiple doses of NP10679 (NCT04007263). We found that NP10679 was well-tolerated and with a half-life of 20 hours, which is amenable to once per day dosing. The only notable side effect in this clinical trial was modest somnolence at higher doses, atypical in that the subject could easily be aroused. The overall results suggest that NP10679 is a candidate for further development for use in acute brain injury, such as ischemic stroke or aneurysmal subarachnoid hemorrhage, as well as for use in neuropsychiatric indications.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Pharmacol Drug Dev

DOI

EISSN

2160-7648

Publication Date

July 2023

Volume

12

Issue

7

Start / End Page

706 / 717

Location

United States

Related Subject Headings

  • Receptors, N-Methyl-D-Aspartate
  • Hydrogen-Ion Concentration
  • Humans
  • 3214 Pharmacology and pharmaceutical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Zaczek, R., Traynelis, S. F., Dingledine, R., Koszalka, G. W., & Laskowitz, D. T. (2023). Phase 1 Clinical Results for NP10679, a pH-sensitive GluN2B-selective N-methyl-d-aspartate Receptor Inhibitor. Clin Pharmacol Drug Dev, 12(7), 706–717. https://doi.org/10.1002/cpdd.1217
Zaczek, Robert, Stephen F. Traynelis, Ray Dingledine, George W. Koszalka, and Daniel T. Laskowitz. “Phase 1 Clinical Results for NP10679, a pH-sensitive GluN2B-selective N-methyl-d-aspartate Receptor Inhibitor.Clin Pharmacol Drug Dev 12, no. 7 (July 2023): 706–17. https://doi.org/10.1002/cpdd.1217.
Zaczek R, Traynelis SF, Dingledine R, Koszalka GW, Laskowitz DT. Phase 1 Clinical Results for NP10679, a pH-sensitive GluN2B-selective N-methyl-d-aspartate Receptor Inhibitor. Clin Pharmacol Drug Dev. 2023 Jul;12(7):706–17.
Zaczek, Robert, et al. “Phase 1 Clinical Results for NP10679, a pH-sensitive GluN2B-selective N-methyl-d-aspartate Receptor Inhibitor.Clin Pharmacol Drug Dev, vol. 12, no. 7, July 2023, pp. 706–17. Pubmed, doi:10.1002/cpdd.1217.
Zaczek R, Traynelis SF, Dingledine R, Koszalka GW, Laskowitz DT. Phase 1 Clinical Results for NP10679, a pH-sensitive GluN2B-selective N-methyl-d-aspartate Receptor Inhibitor. Clin Pharmacol Drug Dev. 2023 Jul;12(7):706–717.
Journal cover image

Published In

Clin Pharmacol Drug Dev

DOI

EISSN

2160-7648

Publication Date

July 2023

Volume

12

Issue

7

Start / End Page

706 / 717

Location

United States

Related Subject Headings

  • Receptors, N-Methyl-D-Aspartate
  • Hydrogen-Ion Concentration
  • Humans
  • 3214 Pharmacology and pharmaceutical sciences